About: ▼Quinupristin + dalfopristin for infections

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : ▼Quinupristin + dalfopristin for infections Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Article
Is Part Of	http://hub.abes.fr/bmj/periodical/dtb/2002/volume_40/issue_2/w
Subject	Articles
Title	▼Quinupristin + dalfopristin for infections
has manifestation of work	http://hub.abes.fr/bmj/periodical/dtb/2002/volume_40/issue_2/B3555EDB394638C5E053120B220A16A6/m/web http://hub.abes.fr/bmj/periodical/dtb/2002/volume_40/issue_2/B3555EDB394638C5E053120B220A16A6/m/print
Abstract	&#9660Quinupristin + dalfopristin* (Synercid-Aventis Pharma Ltd) is a new combination antibacterial product licensed for treating patients with a variety of Gram-positive infections. Here we assess its place in clinical practice.
article type	review-article
publisher identifier	dtdt0202
Alternative Title	▼Quinupristin + dalfopristin for infections
is part of this journal	The British Edition of the Medical Letter on Drugs and Therapeutics
PubMed ID	11892373

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata